| Bioactivity | HBV-IN-19 TFA inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection[1]. |
| Name | HBV-IN-19 TFA |
| CAS | 2241575-60-8 |
| Formula | C26H31F3N2O8 |
| Molar Mass | 556.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Evangelos Aktoudianakis, et al. Compounds for the treatment of hepatitis b virus infection.WO2018144605A1. |
HBV-IN-19 TFA
CAS: 2241575-60-8 F: C26H31F3N2O8 W: 556.53
HBV-IN-19 TFA inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.